2. Search Result
Search Result
Results for "

NOD/SCID or CB.17-SCID mice

" in MedChemExpress (MCE) Product Catalog:

2901

Inhibitors & Agonists

3

Screening Libraries

19

Fluorescent Dye

32

Biochemical Assay Reagents

226

Peptides

1

MCE Kits

111

Inhibitory Antibodies

446

Natural
Products

14

Recombinant Proteins

84

Isotope-Labeled Compounds

7

Antibodies

16

Click Chemistry

64

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100691
    NOD-IN-1
    5+ Cited Publications

    		 NOD-like Receptor (NLR) Inflammation/Immunology
    NOD-IN-1 is a potent mixed inhibitor of nucleotide-binding oligomerization domain (NOD)-like receptors, NOD1 and NOD2, with IC50 of 5.74 μM and 6.45 μM, respectively.
    NOD-IN-1
  • HY-163274
    NOD1 antagonist-1

    		NOD-like Receptor (NLR) Inflammation/Immunology
    NOD1 antagonist-1 (compound 37) exhibits an antagonistic activity towards NOD1 and a weak NOD1/NOD2 selectivity, with IC50s of 9.18 μM and 20.8 μM, respectively .
    NOD1 antagonist-1
  • HY-168023
    NOD1-IN-1

    		NOD-like Receptor (NLR) Inflammation/Immunology
    NOD1/-IN-1 (Compound 2) is a potent RIPK2 inhibitor with an IC50 value of 0.65 nM determined by ADP-Glo assays. NOD1/-IN-1 selectively inhibits the NOD1 pathway (with an IC50 of 33 nM for NOD1), blocking the production of pro-inflammatory cytokines and thereby reducing inflammation. NOD1/-IN-1 is applicable for research in the field of colitis .
    NOD1-IN-1
  • HY-168024
    NOD1/2-IN-1

    		RIP kinase NOD-like Receptor (NLR) Inflammation/Immunology
    NOD1/2-IN-1 (Compound 18) is a potent RIPK2 inhibitor with an IC50 value of 1.4 nM, as determined by the ADP-Glo assay. NOD1/2-IN-1 blocks the production of pro-inflammatory cytokines by inhibiting the NOD1/NOD2 pathways, with IC50 values of 18 nM and 170 nM for NOD1 and NOD2, respectively, thereby reducing inflammatory responses. NOD1/2-IN-1 can be used in studies related to colitis .
    NOD1/2-IN-1
  • HY-170447
    NOD1 antagonist-2

    		NOD-like Receptor (NLR) Inflammation/Immunology
    NOD1 antagonist-2 (compound 66) is an orally active selective antagonist of both human and mouse NOD1. NOD1 antagonist-2 (compound 66) antagonizes NOD1-induced NF-κB and MAPK pathways .
    NOD1 antagonist-2
  • HY-146034
    NOD1/2 antagonist-1

    		NOD-like Receptor (NLR) Inflammation/Immunology Cancer
    NOD1/2 antagonist-1 (compound 36b) is a potent NOD1/2 (nucleotide-binding oligomerization domain-like receptor 1/2) dual antagonist, with IC50 values of 1.13 (NOD1) and 0.77 μM (NOD2), respectively. NOD1/2 antagonist-1 has a acceptable T1/2 (67.6 min). NOD1/2 antagonist-1 (compound 36b) can improve the antitumor efficacy of Paclitaxel (PTX) .
    NOD1/2 antagonist-1
  • HY-176837
    NOD2/TLR4 agonist-1

    		Toll-like Receptor (TLR) NOD-like Receptor (NLR) Inflammation/Immunology
    NOD2/TLR4 agonist-1 (Compound 2) is a NOD2/TLR4 dual agonist. NOD2/TLR4 agonist-1 lacks immunostimulatory activity and serves as an important negative control in research .
    NOD2/TLR4 agonist-1
  • HY-159965
    NOD1-RIPK2-IN-1

    		NOD-like Receptor (NLR) RIP kinase Interleukin Related Inflammation/Immunology
    NOD1-RIPK2-IN-1 (Compound 37) is a NOD1-RIPK2 signaling pathway inhibitor with IC50 values of 42 nM and 1.52 nM for NOD1 and RIPK2, respectively. NOD1-RIPK2-IN-1 reduces the secretion of the pro-inflammatory cytokine IL-8 and can be used in the research of inflammation and immune-related diseases .
    NOD1-RIPK2-IN-1
  • HY-129577
    Aplysin

    		Necroptosis Inflammation/Immunology Cancer
    Aplysin is a brominated sesquiterpene with an isoprene backbone that exhibits hepatoprotective, immunomodulatory, and antitumor activities. Aplysin effectively prevents spontaneous pancreatic necrosis and inflammatory responses in NOD mice .
    Aplysin
  • HY-168158
    NOD2 agonist 3

    		NOD-like Receptor (NLR) Inflammation/Immunology
    NOD2 agonist 3 (Compound 5) is a potent NOD2 agonist, with an EC50 of 111.45 nM. NOD2 agonist 3 shows immunopotentiating effects .
    NOD2 agonist 3
  • HY-105063
    DiaPep277

    		HSP Metabolic Disease Inflammation/Immunology
    DiaPep277 is a 24 amino acid peptide derived from positions 437-460 in HSP60. DiaPep277 arrests the progression of β-cell destruction in NOD mice. DiaPep277 has an immune modulatory effect on diabetogenic T cells in animal models of diabetes .
    DiaPep277
  • HY-168136
    NOD2 agonist 1

    		NOD-like Receptor (NLR) Cancer
    NOD2 agonist 1 (compund 3) is a potent NOD2 agonist (EC50=4.6 nM) .
    NOD2 agonist 1
  • HY-147506
    NOD2 antagonist 1

    		NOD-like Receptor (NLR) Inflammation/Immunology
    NOD2 antagonist 1 (compound 32) is a potent and selective NOD2 antagonist with an IC50 of 5.23 μM. NOD2 antagonist 1 inhibits Muramyl dipeptide (MDP)-induced IL-8 secretion in THP-1 cells and inhibits MDP-induced IL-6, IL-10, TNF-α release in PBMCs .
    NOD2 antagonist 1
  • HY-RS09408
    Nod2 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Nod2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Nod2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Nod2 Rat Pre-designed siRNA Set A
    Nod2 Rat Pre-designed siRNA Set A
  • HY-RS09405
    Nod1 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Nod1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Nod1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Nod1 Rat Pre-designed siRNA Set A
    Nod1 Rat Pre-designed siRNA Set A
  • HY-RS09404
    Nod1 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) NOD-like Receptor (NLR) Others

    Nod1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Nod1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Nod1 Mouse Pre-designed siRNA Set A
    Nod1 Mouse Pre-designed siRNA Set A
  • HY-RS09407
    Nod2 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Nod2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Nod2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Nod2 Mouse Pre-designed siRNA Set A
    Nod2 Mouse Pre-designed siRNA Set A
  • HY-RS09406
    NOD2 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) NOD-like Receptor (NLR) Others

    NOD2 Human Pre-designed siRNA Set A contains three designed siRNAs for NOD2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    NOD2 Human Pre-designed siRNA Set A
    NOD2 Human Pre-designed siRNA Set A
  • HY-RS09403
    NOD1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) NOD-like Receptor (NLR) Others

    NOD1 Human Pre-designed siRNA Set A contains three designed siRNAs for NOD1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    NOD1 Human Pre-designed siRNA Set A
    NOD1 Human Pre-designed siRNA Set A
  • HY-168137
    NOD2 agonist 2

    		NOD-like Receptor (NLR) Inflammation/Immunology
    NOD2 agonist 2 (compound 23) enhanced the antigen presentation of mouse bone marrow-derived dendritic cells (BMDCs), highlighting its potential as a vaccine adjuvant.
    NOD2 agonist 2
  • HY-149428
    AD4
    1 Publications Verification

    		 PROTACs Cancer
    AD4 is an artemisinin derivative that is a proteolytic targeting chimera (PROTAC) targeting PCLAF. AD4 can effectively degrade PCLAF in RS4;11 cells (IC50: 0.6 nM), thereby activating the p21/Rb axis and exerting anti-tumor activity. AD4 also prolonged survival of RS4;11-transplanted NOD/SCID mice, with in vivo efficacy .
    AD4
  • HY-158776
    SLU-10482

    		Parasite Infection
    SLU-10482 is an orally active anti-parasitic agent, that inhibits Cryptosporidium parvum with an IC50 of 0.0687 μM. SLU-10482 exhibits anti-infective efficacy in C. parvum infected mice with an AC50 of 0.0686 μM .
    SLU-10482
  • HY-176561
    IOR-160

    		Casein Kinase HDAC Cancer
    IOR-160 is a dual inhibitor of casein kinase 2 (CK2) and HDACs. IOR-160 exhibits high selectivity for CK2 (IC50 = 1.7 nM) and broad inhibitory activity against HDAC (HDAC 1, 2, 3, and 6 with IC50s of 3.3 nM, 24.0 nM, 3.9 nM, and 13.0 nM, respectively, with low activity for HDAC8). IOR-160 modulates key cellular signaling pathways by inhibiting AKT phosphorylation and increasing acetylated α-tubulin. IOR-160 inhibits tumor growth and reduces tumor burden through dual CK2/HDAC inhibition. IOR-160 is indicated for use in triple-negative breast cancer research .
    IOR-160
  • HY-174437
    FLT3-IN-32

    		FLT3 Apoptosis Cancer
    FLT3-IN-32 is a potent and orally active FLT3 inhibitor. FLT3-IN-32 shows high selectivity for FLT3 and efficiently inhibits FLT3-activating mutations and induces apoptosis. FLT3-IN-32 shows good tolerability in non-tumor bearing mice. FLT3-IN-32 demonstrates outstanding anti-tumor efficacy in MV4-11 bearing NOD/SCID mice, prolonging the survival noticeably. FLT3-IN-32 can be used for the research of acute myeloid leukemia .
    FLT3-IN-32
  • HY-164039
    Talorasib

    		Others Cancer
    Talorasib (compound 1-2) has antitumor activity .
    Talorasib
  • HY-172617
    APD-94

    		BMI1 Microtubule/Tubulin Apoptosis Cancer
    APD-94 is a dual inhibitor targeting tubulin and Bmi-1. APD-94 interfers tubulin normal polymerization. APD-94 suppresses the expression of Bmi-1. APD-94 causes cell cycle arrest at the G2/M phase in cancer cells and induces apoptosis, thus inhibiting cancer cell proliferation. APD-94 represses the growth of HT29 cell xenografts in NOD/SCID mice. APD-94 can be used for colorectal cancer study .
    APD-94
  • HY-P991433
    BIIB036

    		TNF Receptor Cancer
    BIIB036 is a human IgG1 monoclonal antibody (mAb) targeting TNFRSF12A/Fn14. BIIB036 inhibits the growth of patient-derived primary colorectal tumors in SCID mice .
    BIIB036
  • HY-155864
    AJ2-30

    		NOD-like Receptor (NLR) mTOR Oligopeptide Cotransporter Inflammation/Immunology
    AJ2-30 is a SLCl5A4 inhibitor. AJ2-30 inhibits endolysosomal TLR7-9-mediated mTOR activation. AJ2-30 blocks endogenous NOD signaling. AJ2-30 can be used in inflammation studies .
    AJ2-30
  • HY-175455
    LYA914

    		PROTACs Androgen Receptor Akt Cancer
    LYA914 is an orally active AR/AR-V7 PROTAC degrader. LYA914 targets the proteolytic degradation of the conserved DNA binding domain (DBD) of the androgen receptor (AR). LYA914 exhibits potent antiproliferative effects in Enzalutamide (HY-70002)-insensitive/resistant cells. LYA914 inhibits tumor growth in VCaP/LNCaP tumor mouse models. LYA914 can be used to study castration-resistant prostate cancer (CRPC). (Pink: AR-DBD ligand-1: HY-175456, Blue: Thalidomide: HY-14658, Pink + Black: AR-DBD ligand-Linker Conjugate 1: HY-175457, Black: Boc-piperidine-oxopiperidin: HY-175458) .
    LYA914
  • HY-118912
    BMH-9

    		MDM-2/p53 Inflammation/Immunology Cancer
    BMH-9 (Compound Z54) is a modulator for nuclear receptor subfamily 2, group F, member 6 (NR2F6) (also known as nuclear orphan receptor Ear2) . BMH-9 is an activator for p53 signaling pathway through interaction with DNA. BMH-9 inhibits proliferation of human cancer cells, exhibits antitumor efficacy in NOD-SCID mouse models .
    BMH-9
  • HY-175541
    TQ-3959

    		PROTACs Btk Cancer
    TQ-3959 is an orally active BTK PROTAC degrader, with a DC50 of 14.6 nM. TQ-3959 exerts antiproliferative activity against both wild-type BTK and C481S mutant BTK cell lines. TQ-3959 exhibits tumor growth inhibition in female NOD-SCID mice bearing TMD-8 xenografts. TQ-3959 can be used in the research on B-cell malignancies such as lymphoma.(Pink: BTK ligand (HY-150885), Blue: CRBN Ligand (HY-W733888), Black: Linker (HY-W061884), E3 ligase ligand-linker conjugate (HY-175545)) .
    TQ-3959
  • HY-172954
    Androgen receptor ligand 1

    		Androgen Receptor Ligands for Target Protein for PROTAC Cancer
    Androgen receptor ligand 1 is an androgen receptor (AR) ligand. Androgen receptor ligand 1 binds to CRBN E3 ligase via a linker to form an AR PROTAC degrader. Androgen receptor ligand 1 can be used in the study of prostate cancer .
    Androgen receptor ligand 1
  • HY-W099584
    Butyl tetradecanoate

    Myristic SCID butyl ester

    		 Biochemical Assay Reagents Others
    Butyl tetradecanoate is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
    Butyl tetradecanoate
  • HY-P991669
    IGN523

    		Caspase Apoptosis Cancer
    IGN523 is an anti-CD98 antibody (hCD98, KD = 0.55 nM). IGN523 induces antibody-dependent cell-mediated cytotoxicity (ADCC) activity, lysosomal membrane permeabilization, and inhibition of essential amino acid transport, ultimately leading to caspase-3 and caspase-7-mediated apoptosis of tumor cells. IGN523 inhibits tumor growth in multiple tumor xenograft models. IGN523 is useful in the research of non-small cell lung cancer (NSCLC), acute myeloid leukemia (AML), and other cancers. .
    IGN523
  • HY-125858
    MI-1061
    1 Publications Verification

    		 MDM-2/p53 E1/E2/E3 Enzyme Apoptosis Cancer
    MI-1061 is a potent, orally bioavailable, and chemically stable MDM2 (MDM2-p53 interaction) inhibitor (IC50=4.4 nM; Ki=0.16 nM). MI-1061 potently activates p53 and induces apoptosis in the SJSA-1 xenograft tumor tissue in mice. Anti-tumor activity .
    MI-1061
  • HY-125858A
    MI-1061 TFA
    1 Publications Verification

    		 MDM-2/p53 E1/E2/E3 Enzyme Apoptosis Cancer
    MI-1061 TFA is a potent, orally bioavailable, and chemically stable MDM2 (MDM2-p53 interaction) inhibitor (IC50=4.4 nM; Ki=0.16 nM). MI-1061 TFA potently activates p53 and induces apoptosis in the SJSA-1 xenograft tumor tissue in mice. Anti-tumor activity .
    MI-1061 TFA
  • HY-169240
    MX69-102

    		MDM-2/p53 Cancer
    MX69-102 (compound MX69-102) is an MDM-2/p53 inhibitor, inducing MDM2 degradation, resulting in p53 activation and cancer cell apoptosis. MX69-102 shows effective inhibition on xenografted human MDM2-overexpressing ALL in SCID mice. .
    MX69-102
  • HY-P99588
    Stamulumab
    1 Publications Verification

    MYO-029

    		 TGF-β Receptor Metabolic Disease
    Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research .
    Stamulumab
  • HY-P991542
    GBR-401

    		CD19 Cancer
    GBR-401 is a humanized anti-CD19 monoclonal antibody with high affinity for FcγRIIIa. GBR-401 exerts a potent in vitro and in vivo cytotoxic activity against various B-cell malignancies. GBR-401 induces cell death by antibody dependent cellular cytotoxicity (ADCC) and direct killing effect. GBR-401 demonstrates potent activity of depleting malignant B cells and prolongs mice survival in multiple xenograft severe combined immunodeficiency (SCID) mice models .
    GBR-401
  • HY-P5544
    M-TriDAP

    N-Acetylmuramyl-L-Ala-γ-D-Glu-meso-diaminopimelic acid

    		 NOD-like Receptor (NLR) Others
    M-TriDAP (N-Acetylmuramyl-L-Ala-γ-D-Glu-meso-diaminopimelic acid) is a NOD1/2 agoist and biological active peptide .
    M-TriDAP
  • HY-P99488
    Briquilimab

    JSP-191; AMG-191

    		 c-Kit Inflammation/Immunology Cancer
    Briquilimab (JSP-191 or AMG-191) is a humanized IgG1 monoclonal antibody that binds human CD117 (c-Kit). Briquilimab blocks the interaction between CD117 receptor and stem cell factor on various CD117 expressing tissues. Briquilimab can lead to inhibition of SCF/c-Kit signaling and MC apoptosis. Briquilimab is a non-toxic approach to target and deplete HSC, enabling blood and immune reconstitution with minimal toxicity with the other agents being used for transient immune suppression to prevent immunologic rejection. Briquilimab can be used in various disease research such as severe combined immunodeficiency (SCID), myelodyplastic syndromes (MDS), acute myeloid leukemia (AML), chronic spontaneous urticarial (CSU), chronic inducible urticarial (CIndU) and asthema .
    Briquilimab
  • HY-P5544A
    M-TriDAP TFA

    N-Acetylmuramyl-L-Ala-γ-D-Glu-meso-diaminopimelic acid TFA

    		 NOD-like Receptor (NLR) Others
    M-TriDAP (N-Acetylmuramyl-L-Ala-γ-D-Glu-meso-diaminopimelic acid) TFA is a NOD1/2 agoist and biological active peptide .
    M-TriDAP TFA
  • HY-135746
    OR-1896
    2 Publications Verification

    		 Potassium Channel Phosphodiesterase (PDE) Drug Metabolite Apoptosis Cardiovascular Disease
    OR-1896 is an active long-lived metabolite of Levosimendan. OR-1896 is a highly selective phosphodiesterase (PDE) III isoform inhibitor and a powerful vasodilator. OR-1896 can open ATP-sensitive K + channels and has Ca 2+-sensitizing effect. OR-1896 mitigates cardiomyocyte apoptosis, cardiac remodeling and myocardial inflammation .
    OR-1896
  • HY-W050000
    OR-1855
    1 Publications Verification

    		 Potassium Channel Phosphodiesterase (PDE) Autophagy Cardiovascular Disease
    OR-1855, an active metabolite of Levosimendan, has effect on human myometrial contractility. Levosimendan is a calcium sensitiser used in the management of acutely decompensated congestive heart failure .
    OR-1855
  • HY-P2300
    Cyclo(Arg-Gly-Asp-D-Phe-Cys)
    1 Publications Verification

    Cyclo(RGDfC)

    		 Integrin Cancer
    Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC), a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) can be used in the research of tumors .
    Cyclo(Arg-Gly-Asp-D-Phe-Cys)
  • HY-P5396
    GAD65 (524-543)

    		Amino Acid Decarboxylase Others
    GAD65 (524-543) is a biological active peptide. (This is amino acids 524 to 543 fragment of glutamic acid decarboxylase 65 (GAD65). It is one of the first fragments of this islet antigen to induce proliferative T cell responses in the non-obese diabetic (NOD) mouse model of spontaneous autoimmune diabetes. This peptide is a specific, possibly low affinity, stimulus for the spontaneously arising diabetogenic T cell clone BDC2.5. Immunization with p524–543 increases the susceptibility of the NOD mice to type 1 diabetes induced by the adoptive transfer of BDC2.5 T cells.)
    GAD65 (524-543)
  • HY-136555
    GSK717
    5+ Cited Publications

    		 NOD-like Receptor (NLR) Inflammation/Immunology
    GSK717 is a potent, selective NOD2 (nucleotide-binding oligomerization domain 2) inhibitor. GSK717 inhibits muramyl dipeptide (MDP)-induced NOD2-mediated signaling, with an IC50 of 400 nM for MDP-stimulated IL-8 secretion in HEK293/hNOD2 cells .
    GSK717
  • HY-P5489
    IGRP(206-214)

    		IFNAR Metabolic Disease Inflammation/Immunology
    IGRP(206-214) is a biological active peptide. IGRP(206-214) corresponds to residues 206-214 of murine islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP). IGRP(206-214) is T cells specific for proinsulin and IGRP induces diabetes in non-obese diabetic (NOD) mice .
    IGRP(206-214)
  • HY-135746R
    OR-1896 (Standard)

    		Reference Standards Potassium Channel Phosphodiesterase (PDE) Drug Metabolite Apoptosis Cardiovascular Disease
    7-epi-Taxol (Standard) is the analytical standard of 7-epi-Taxol. This product is intended for research and analytical applications. 7-epi-Taxol is an active metabolite of taxol, with activity comparable to that of taxol against cell replication, promoting microtubule bundle formation and against microtubule depolymerization.
    OR-1896 (Standard)
  • HY-P10823
    RI-OR2

    		Amyloid-β Neurological Disease
    RI-OR2, a retro-inverso peptide, is an amyloid-β (Aβ) oligomerization inhibitor. RI-OR2 binds to immobilized β-Amyloid (1-42) (HY-P1363A) monomers and fibrils, with an apparent Kd of 9-12 μM, and also acted as an inhibitor of Aβ(1-42) fibril extension .
    RI-OR2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: